- Home
- PAVM
PAVM
PAVmed Inc.
as 12-27-2024 12:39pm EST
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 12.7M | IPO Year: | 2016 |
| Target Price: | $19.00 | AVG Volume (30 days): | 225.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.57 - $4.44 | Next Earning Date: | 11-14-2024 |
| Revenue: | $4,034,000 | Revenue Growth: | 166.27% |
| Revenue Growth (this year): | 52.9% | Revenue Growth (next year): | 248.84% |
Latest PAVmed Inc. News
PAVM Breaking Stock News: Dive into PAVM Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
PR Newswire
8 days ago
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
PR Newswire
16 days ago
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
PR Newswire
24 days ago
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
PR Newswire
a month ago
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
PR Newswire
a month ago
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Simply Wall St.
a month ago
PAVmed Third Quarter 2024 Earnings: Misses Expectations
Thomson Reuters StreetEvents
a month ago
Q3 2024 PAVmed Inc Earnings Call
Compare PAVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PAVM PAVmed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.